EPO and anemia (phenotype): Patients treated with a new class of drug called hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), which inhibit the degradation of HIF-α by prolyl hydroxylases, recover from their anemia with EPO produced at physiological levels rather than the pharmacological levels of recombinant EPO [69].